{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:32:38Z","timestamp":1792269158943,"version":"4.4.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T00:00:00Z","timestamp":1699488000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T00:00:00Z","timestamp":1699488000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s12325-023-02650-7","type":"journal-article","created":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T08:23:54Z","timestamp":1699518234000},"page":"1-13","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Unmet Needs in the Acute Treatment of Migraine"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6655-9905","authenticated-orcid":false,"given":"Enrico","family":"Bentivegna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Galastri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilara","family":"Onan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Martelletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,9]]},"reference":[{"issue":"1","key":"2650_CR1","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s10194-020-01208-0","volume":"21","author":"TJ Steiner","year":"2020","unstructured":"Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava Z. Lifting the Burden: the Global Campaign against Headache. Migraine remains second among the world\u2019s causes of disability, and first among young women: findings from GBD2019. J Headache Pain. 2020;21(1):137. https:\/\/doi.org\/10.1186\/s10194-020-01208-0. (PMID: 33267788; PMCID: PMC7708887).","journal-title":"J Headache Pain"},{"issue":"19","key":"2650_CR2","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1056\/NEJMra1915327","volume":"383","author":"AM Migraine","year":"2020","unstructured":"Migraine AM. N Engl J Med. 2020;383(19):1866\u201376. https:\/\/doi.org\/10.1056\/NEJMra1915327. (PMID: 33211930).","journal-title":"N Engl J Med"},{"key":"2650_CR3","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1046\/j.1468-2982.2002.00404.x","volume":"22","author":"MD Ferrari","year":"2002","unstructured":"Ferrari MD, Goadsby PJ, Roon KI, et al. Triptans (serotonin, 5-HT1B\/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia. 2002;22:633\u201358.","journal-title":"Cephalalgia"},{"key":"2650_CR4","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-97359-9_4","volume-title":"Migraine in medicine","author":"P Martelletti","year":"2022","unstructured":"Martelletti P. Treatment. In: Martelletti P, editor. Migraine in medicine. Cham: Springer; 2022. https:\/\/doi.org\/10.1007\/978-3-030-97359-9_4."},{"issue":"1","key":"2650_CR5","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s10194-020-01130-5","volume":"21","author":"S Sacco","year":"2020","unstructured":"Sacco S, Braschinsky M, Ducros A, Lampl C, Little P, van den Brink AM, Pozo-Rosich P, Reuter U, de la Torre ER, Sanchez Del Rio M, Sinclair AJ, Katsarava Z, Martelletti P. European headache federation consensus on the definition of resistant and refractory migraine: Developed with the endorsement of the European Migraine & Headache Alliance (EMHA). J Headache Pain. 2020;21(1):76. https:\/\/doi.org\/10.1186\/s10194-020-01130-5. (PMID: 32546227; PMCID: PMC7296705).","journal-title":"J Headache Pain"},{"key":"2650_CR6","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1046\/j.1526-4610.2003.03073.x","volume":"43","author":"G Geraud","year":"2003","unstructured":"Geraud G, Keywood C, Senard JM. Migraine headache recurrence: relationship to clinical, pharmacological, and pharmacokinetic properties of triptans. Headache. 2003;43:376\u201388.","journal-title":"Headache"},{"key":"2650_CR7","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s10194-011-0388-3","volume":"12","author":"A Negro","year":"2011","unstructured":"Negro A, Martelletti P. Chronic migraine plus medication overuse headache: two entities or not? J Headache Pain. 2011;12:593\u2013601.","journal-title":"J Headache Pain"},{"key":"2650_CR8","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1111\/j.1526-4610.2004.04078.x","volume":"44","author":"D Dodick","year":"2004","unstructured":"Dodick D, Lipton RB, Martin V, et al. Consensus statement: cardiovascular safety profile of triptans (5- HT1B\/1D agonists) in the acute treatment of migraine. Headache. 2004;44:414\u201325.","journal-title":"Headache"},{"key":"2650_CR9","doi-asserted-by":"publisher","first-page":"114147","DOI":"10.1016\/j.bcp.2020.114147","volume":"180","author":"S Bindu","year":"2020","unstructured":"Bindu S, Mazumder S, Bandyopadhyay U. Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: a current perspective. Biochem Pharmacol. 2020;180:114147. https:\/\/doi.org\/10.1016\/j.bcp.2020.114147. (Epub 2020 Jul 10. PMID: 32653589; PMCID: PMC7347500).","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"2650_CR10","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s10194-021-01224-8","volume":"22","author":"TT Takahashi","year":"2021","unstructured":"Takahashi TT, Ornello R, Quatrosi G, Torrente A, Albanese M, Vigneri S, Guglielmetti M, Maria De Marco C, Dutordoir C, Colangeli E, Fuccaro M, Di Lenola D, Spuntarelli V, Pilati L, Di Marco S, Van Dycke A, Abdullahi RA, Maassen van den Brink A, Martelletti P, European Headache Federation School of Advanced Studies (EHF-SAS). Medication overuse and drug addiction: a narrative review from addiction perspective. J Headache Pain. 2021;22(1):32. https:\/\/doi.org\/10.1186\/s10194-021-01224-8.","journal-title":"J Headache Pain"},{"issue":"6","key":"2650_CR11","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s10194-011-0388-3","volume":"12","author":"A Negro","year":"2011","unstructured":"Negro A, Martelletti P. Chronic migraine plus medication overuse headache: two entities or not? J Headache Pain. 2011;12(6):593\u2013601. https:\/\/doi.org\/10.1007\/s10194-011-0388-3. (Epub 2011 Sep 22. PMID: 21938457; PMCID: PMC3208042).","journal-title":"J Headache Pain"},{"issue":"6","key":"2650_CR12","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1111\/head.12550","volume":"55","author":"WJ Becker","year":"2015","unstructured":"Becker WJ. Acute migraine treatment in adults. Headache. 2015;55(6):778\u201393. https:\/\/doi.org\/10.1111\/head.12550. (Epub 2015 Apr 15 PMID: 25877672).","journal-title":"Headache"},{"issue":"Suppl 1","key":"2650_CR13","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/j.1526-4610.2012.02140.x","volume":"52","author":"SJ Tepper","year":"2012","unstructured":"Tepper SJ. Opioids should not be used in migraine. Headache. 2012;52(Suppl 1):30\u20134. https:\/\/doi.org\/10.1111\/j.1526-4610.2012.02140.x. (PMID: 22540203).","journal-title":"Headache"},{"issue":"1","key":"2650_CR14","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s10194-018-0899-2","volume":"20","author":"TJ Steiner","year":"2019","unstructured":"Steiner TJ, Jensen R, Katsarava Z, Linde M, MacGregor EA, Osipova V, Paemeleire K, Olesen J, Peters M, Martelletti P. Aids to management of headache disorders in primary care (2nd edition): on behalf of the European Headache Federation and Lifting the Burden: the Global Campaign against Headache. J Headache Pain. 2019;20(1):57. https:\/\/doi.org\/10.1186\/s10194-018-0899-2. (PMID: 31113373; PMCID: PMC6734476).","journal-title":"J Headache Pain"},{"key":"2650_CR15","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1517\/13543784.2012.681044","volume":"21","author":"A Negro","year":"2012","unstructured":"Negro A, Lionetto L, Simmaco M, et al. CGRP receptor antagonists: an expanding drug class for acute migraine? Expert Opin Investig Drugs. 2012;21:807\u201318.","journal-title":"Expert Opin Investig Drugs"},{"issue":"6","key":"2650_CR16","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1080\/13543784.2019.1618830","volume":"28","author":"A Negro","year":"2019","unstructured":"Negro A, Martelletti P. Gepants for the treatment of migraine. Expert Opin Investig Drugs. 2019;28(6):555\u201367. https:\/\/doi.org\/10.1080\/13543784.2019.1618830. (Epub 2019 May 17 PMID: 31081399).","journal-title":"Expert Opin Investig Drugs"},{"issue":"10268","key":"2650_CR17","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0140-6736(20)32544-7","volume":"397","author":"R Croop","year":"2021","unstructured":"Croop R, Lipton RB, Kudrow D, Stock DA, Kamen L, Conway CM, Stock EG, Coric V, Goadsby PJ. Oral rimegepant for preventive treatment of migraine: a phase 2\/3, randomized, double-blind, placebo-controlled trial. Lancet. 2021;397(10268):51\u201360. https:\/\/doi.org\/10.1016\/S0140-6736(20)32544-7. (Epub 2020 Dec 15 PMID: 33338437).","journal-title":"Lancet"},{"issue":"10200","key":"2650_CR18","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/S0140-6736(19)31606-X","volume":"394","author":"R Croop","year":"2019","unstructured":"Croop R, Goadsby PJ, Stock DA, Conway CM, Forshaw M, Stock EG, Coric V, Lipton RB. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomized, phase 3, double-blind, placebo-controlled trial. Lancet. 2019;394(10200):737\u201345. https:\/\/doi.org\/10.1016\/S0140-6736(19)31606-X. (Epub 2019 Jul 13 PMID: 31311674).","journal-title":"Lancet"},{"issue":"19","key":"2650_CR19","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1001\/jama.2019.16711","volume":"322","author":"RB Lipton","year":"2019","unstructured":"Lipton RB, Dodick DW, Ailani J, Lu K, Finnegan M, Szegedi A, Trugman JM. Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial. JAMA. 2019;322(19):1887\u201398. https:\/\/doi.org\/10.1001\/jama.2019.16711. (Erratum in: JAMA. 2020 Apr 7;323(13):1318. PMID: 31742631; PMCID: PMC6865323).","journal-title":"JAMA"},{"issue":"7","key":"2650_CR20","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s40265-020-01301-3","volume":"80","author":"LJ Scott","year":"2020","unstructured":"Scott LJ. Rimegepant: first approval. Drugs. 2020;80(7):741\u20136. https:\/\/doi.org\/10.1007\/s40265-020-01301-3. (PMID: 32270407).","journal-title":"Drugs"},{"key":"2650_CR21","unstructured":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012\u2013. Rimegepant. 2021 Jul 20. PMID: 34324285."},{"issue":"3","key":"2650_CR22","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1080\/14737175.2022.2049758","volume":"22","author":"D Scuteri","year":"2022","unstructured":"Scuteri D, Tonin P, Nicotera P, Bagetta G, Corasaniti MT. Real world considerations for newly approved CGRP receptor antagonists in migraine care. Expert Rev Neurother. 2022;22(3):221\u201330. https:\/\/doi.org\/10.1080\/14737175.2022.2049758. (Epub 2022 Mar 14 PMID: 35240905).","journal-title":"Expert Rev Neurother"},{"issue":"3","key":"2650_CR23","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/WCO.0000000000000806","volume":"33","author":"D Moreno-Ajona","year":"2020","unstructured":"Moreno-Ajona D, P\u00e9rez-Rodr\u00edguez A, Goadsby PJ. Gepants, calcitonin-gene-related peptide receptor antagonists: what could be their role in migraine treatment? Curr Opin Neurol. 2020;33(3):309\u201315. https:\/\/doi.org\/10.1097\/WCO.0000000000000806. (PMID: 32251023).","journal-title":"Curr Opin Neurol"},{"issue":"1","key":"2650_CR24","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s40265-021-01644-5","volume":"82","author":"ED Deeks","year":"2022","unstructured":"Deeks ED. Atogepant: first approval. Drugs. 2022;82(1):65\u201370. https:\/\/doi.org\/10.1007\/s40265-021-01644-5. (PMID: 34813050).","journal-title":"Drugs"},{"issue":"12","key":"2650_CR25","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.3390\/pharmaceutics12121180","volume":"12","author":"D Szkutnik-Fiedler","year":"2020","unstructured":"Szkutnik-Fiedler D. Pharmacokinetics, pharmacodynamics and drug-drug interactions of new anti-migraine drugs-lasmiditan, gepants, and calcitonin-gene-related peptide (CGRP) receptor monoclonal antibodies. Pharmaceutics. 2020;12(12):1180. https:\/\/doi.org\/10.3390\/pharmaceutics12121180. (PMID: 33287305; PMCID: PMC7761673).","journal-title":"Pharmaceutics"},{"issue":"1","key":"2650_CR26","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s10194-022-01394-z","volume":"23","author":"JCA Edvinsson","year":"2022","unstructured":"Edvinsson JCA, Maddahi A, Christiansen IM, Reducha PV, Warfvinge K, Sheykhzade M, Edvinsson L, Haanes KA. Lasmiditan and 5-Hydroxytryptamine in the rat trigeminal system; expression, release and interactions with 5-HT1 receptors. J Headache Pain. 2022;23(1):26. https:\/\/doi.org\/10.1186\/s10194-022-01394-z. (PMID: 35177004; PMCID: PMC8903724).","journal-title":"J Headache Pain"},{"issue":"1","key":"2650_CR27","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s10194-020-01132-3","volume":"21","author":"DB Clemow","year":"2020","unstructured":"Clemow DB, Johnson KW, Hochstetler HM, Ossipov MH, Hake AM, Blumenfeld AM. Lasmiditan mechanism of action\u2014review of a selective 5-HT1F agonist. J Headache Pain. 2020;21(1):71. https:\/\/doi.org\/10.1186\/s10194-020-01132-3. (PMID: 32522164; PMCID: PMC7288483).","journal-title":"J Headache Pain"},{"issue":"18","key":"2650_CR28","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1007\/s40265-019-01225-7","volume":"79","author":"YN Lamb","year":"2019","unstructured":"Lamb YN. Lasmiditan: first approval. Drugs. 2019;79(18):1989\u201396. https:\/\/doi.org\/10.1007\/s40265-019-01225-7.","journal-title":"Drugs"},{"issue":"11","key":"2650_CR29","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1080\/14656566.2022.2102420","volume":"23","author":"E Bentivegna","year":"2022","unstructured":"Bentivegna E, Luciani M, Ferrari V, Galastri S, Baldari F, Scarso F, Lamberti PA, Martelletti P. Recently approved and emerging drug options for migraine prophylaxis. Expert Opin Pharmacother. 2022;23(11):1325\u201335. https:\/\/doi.org\/10.1080\/14656566.2022.2102420. (Epub 2022 Jul 25 PMID: 35850597).","journal-title":"Expert Opin Pharmacother"},{"key":"2650_CR30","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/S1474-4422(19)30185-1","volume":"18","author":"M Ashina","year":"2019","unstructured":"Ashina M, Hansen JM, Do TP, MeloCarrillo A, Burstein R, Moskowitz MA. Migraine and the trigeminovascular system-40 years and counting. Lancet Neurol. 2019;18:795\u2013804.","journal-title":"Lancet Neurol"},{"key":"2650_CR31","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018 Jan;38(1):1\u2013211.","DOI":"10.1177\/0333102417738202"},{"issue":"1","key":"2650_CR32","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s10194-022-01431-x","volume":"23","author":"S Sacco","year":"2022","unstructured":"Sacco S, Amin FM, Ashina M, Bendtsen L, Deligianni CI, Gil-Gouveia R, Katsarava Z, MaassenVanDenBrink A, Martelletti P, Mitsikostas DD, Ornello R, Reuter U, Sanchez-Del-Rio M, Sinclair AJ, Terwindt G, Uluduz D, Versijpt J, Lampl C. European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update. J Headache Pain. 2022;23(1):67. https:\/\/doi.org\/10.1186\/s10194-022-01431-x. (PMID: 35690723; PMCID: PMC9188162).","journal-title":"J Headache Pain"},{"issue":"23","key":"2650_CR33","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1001\/jama.2021.7665","volume":"325","author":"PK Winner","year":"2021","unstructured":"Winner PK, McAllister P, Chakhava G, Ailani J, Ettrup A, Josiassen MK, et al. Effects of intravenous eptinezumab vs placebo on headache pain and most bothersome symptom when initiated during a migraine attack: a randomized clinical trial. JAMA. 2021;325(23):2348\u201356. https:\/\/doi.org\/10.1001\/jama.2021.7665.","journal-title":"JAMA"},{"key":"2650_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-021-01252-4","author":"S Sacco","year":"2021","unstructured":"Sacco S, Lampl C, van MaassendenBrink A, Caponnetto V, Braschinsky M, Ducros A, Little P, Pozo-Rosich P, Reuter U, Ruiz E, de laTorre D, SanchezRio M, Sinclair AJ, Martelletti P, Katsarava Z, Burden and Attitude to Resistant and Refractory (BARR) Study Group. Burden and attitude to resistant and refractory migraine: a survey from the European headache federation with the endorsement of the European migraine & headache alliance. J Headache Pain. 2021. https:\/\/doi.org\/10.1186\/s10194-021-01252-4.","journal-title":"J Headache Pain"},{"issue":"8","key":"2650_CR35","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1080\/14712598.2020.1751114","volume":"20","author":"C Chan","year":"2022","unstructured":"Chan C, Goadsby PJ. CGRP pathway monoclonal antibodies for cluster headache. Expert Opin Biol Ther. 2022;20(8):947\u201353. https:\/\/doi.org\/10.1080\/14712598.2020.1751114. (Epub 2020 Apr 28 PMID: 32241175).","journal-title":"Expert Opin Biol Ther"},{"issue":"2","key":"2650_CR36","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/head.13691","volume":"60","author":"HC Detke","year":"2020","unstructured":"Detke HC, Millen BA, Zhang Q, Samaan K, Ailani J, Dodick DW, et al. Rapid onset of effect of galcanezumab for the prevention of episodic migraine: analysis of the EVOLVE studies. Headache. 2020;60(2):348\u201359. https:\/\/doi.org\/10.1111\/head.13691.","journal-title":"Headache"},{"issue":"1","key":"2650_CR37","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s10194-018-0923-6","volume":"19","author":"T Schwedt","year":"2018","unstructured":"Schwedt T, Reuter U, Tepper S, Ashina M, Kudrow D, Broessner G, et al. Early onset of efficacy with erenumab in patients with episodic and chronic migraine. J Headache Pain. 2018;19(1):92\u201392. https:\/\/doi.org\/10.1186\/s10194-018-0923-6.","journal-title":"J Headache Pain"},{"issue":"1","key":"2650_CR38","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s10194-022-01393-0","volume":"23","author":"T Takeshima","year":"2022","unstructured":"Takeshima T, Nakai M, Shibasaki Y, Ishida M, Kim B-K, Ning X, et al. Early onset of efficacy with fremanezumab in patients with episodic and chronic migraine: subanalysis of two phase 2b\/3 trials in Japanese and Korean patients. J Headache Pain. 2022;23(1):24\u201324. https:\/\/doi.org\/10.1186\/s10194-022-01393-0.","journal-title":"J Headache Pain"},{"issue":"1","key":"2650_CR39","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s10194-021-01328-1","volume":"22","author":"E Caronna","year":"2021","unstructured":"Caronna E, Gallardo VJ, Alpuente A, Torres-Ferrus M, Pozo-Rosich P. Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months. J Headache Pain. 2021;22(1):120\u2013120. https:\/\/doi.org\/10.1186\/s10194-021-01328-1.","journal-title":"J Headache Pain"},{"issue":"1","key":"2650_CR40","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s40001-022-00716-w","volume":"27","author":"H Sevivas","year":"2022","unstructured":"Sevivas H, Fresco P. Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review. Eur J Med Res. 2022;27(1):86. https:\/\/doi.org\/10.1186\/s40001-022-00716-w. (PMID: 35659086; PMCID: PMC9167529).","journal-title":"Eur J Med Res"},{"issue":"8","key":"2650_CR41","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1111\/head.13596","volume":"59","author":"RW Evans","year":"2019","unstructured":"Evans RW. Raynaud\u2019s phenomenon associated with calcitonin gene -related peptide monoclonal antibody antagonists. Headache. 2019;59(8):1360\u20134.","journal-title":"Headache"},{"issue":"7","key":"2650_CR42","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1177\/0333102420983292","volume":"41","author":"R Noseda","year":"2021","unstructured":"Noseda R, Bedussi F, Gobbi C, Zecca C, Ceschi A. Safety profile of erenumab, galcanezumab and fremanezumab in pregnancy and lactation: analysis of the WHO pharmacovigilance database. Cephalalgia. 2021;41(7):789-798 66.","journal-title":"Cephalalgia"},{"key":"2650_CR43","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1002\/eji.1830260718","volume":"26","author":"NE Simister","year":"1996","unstructured":"Simister NE, Story CM, Chen HL, et al. An IgG-transporting Fc receptor expressed in the syncytiotrophoblast of human placenta. Eur J Immunol. 1996;26:1527\u201331.","journal-title":"Eur J Immunol"},{"key":"2650_CR44","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1177\/0333102418821662","volume":"39","author":"DW Dodick","year":"2019","unstructured":"Dodick DW. CGRP ligand and receptor monoclonal antibodies for migraine prevention: evidence review and clinical implications. Cephalalgia. 2019;39:445\u201358.","journal-title":"Cephalalgia"},{"issue":"19","key":"2650_CR45","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1212\/WNL.0000000000201332","volume":"99","author":"J Ailani","year":"2022","unstructured":"Ailani J, Kaiser EA, Mathew PG, McAllister P, Russo AF, V\u00e9lez C, Ramajo AP, Abdrabboh A, Xu C, Rasmussen S, Tepper SJ. Role of calcitonin gene-related peptide on the gastrointestinal symptoms of migraine-clinical considerations: a narrative review. Neurology. 2022;99(19):841\u201353. https:\/\/doi.org\/10.1212\/WNL.0000000000201332. (Epub ahead of print. PMID: 36127137; PMCID: PMC9651456).","journal-title":"Neurology"},{"issue":"1","key":"2650_CR46","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s10194-020-01143-0","volume":"21","author":"A Russo","year":"2020","unstructured":"Russo A, Silvestro M, Scotto di Clemente F, Trojsi F, Bisecco A, Bonavita S, et al. Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience. J Headache Pain. 2020;21(1):69.","journal-title":"J Headache Pain"},{"issue":"5","key":"2650_CR47","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1111\/ane.12906","volume":"137","author":"TP Do","year":"2018","unstructured":"Do TP, Hvedstrup J, Schytz HW. Botulinum toxin: a review of the mode of action in migraine. Acta Neurol Scand. 2018;137(5):442\u201351. https:\/\/doi.org\/10.1111\/ane.12906.","journal-title":"Acta Neurol Scand"},{"issue":"1","key":"2650_CR48","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s10194-018-0921-8","volume":"19","author":"L Bendtsen","year":"2018","unstructured":"Bendtsen L, Sacco S, Ashina M, Mitsikostas D, Ahmed F, Pozo-Rosich P, Martelletti P. Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation. J Headache Pain. 2018;19(1):91. https:\/\/doi.org\/10.1186\/s10194-018-0921-8. (PMID: 30259200; PMCID: PMC6755553).","journal-title":"J Headache Pain"},{"issue":"6","key":"2650_CR49","doi-asserted-by":"publisher","first-page":"CD011616","DOI":"10.1002\/14651858.CD011616.pub2","volume":"6","author":"CP Herd","year":"2018","unstructured":"Herd CP, Tomlinson CL, Rick C, Scotton WJ, Edwards J, Ives N, Clarke CE, Sinclair A. Botulinum toxins for the prevention of migraine in adults. Cochrane Database Syst Rev. 2018;6(6):CD011616. https:\/\/doi.org\/10.1002\/14651858.CD011616.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"2650_CR50","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1111\/head.14153","volume":"61","author":"J Ailani","year":"2021","unstructured":"Ailani J, Burch RC, Robbins MS, The Board of Directors of the American Headache Society. The American Headache Society Consensus Statement: update on integrating new migraine treatments into clinical practice. Headache. 2021;61:1021\u201339. https:\/\/doi.org\/10.1111\/head.14153.","journal-title":"Headache"},{"issue":"8","key":"2650_CR51","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1111\/head.12154","volume":"53","author":"RB Lipton","year":"2013","unstructured":"Lipton RB, Buse DC, Serrano D, Holland S, Reed ML. Examination of unmet treatment needs among persons with episodic migraine: results of the American Migraine Prevalence and Prevention (AMPP) Study. Headache. 2013;53(8):1300\u201311. https:\/\/doi.org\/10.1111\/head.12154. (Epub 2013 Jul 23 PMID: 23879870).","journal-title":"Headache"},{"issue":"1","key":"2650_CR52","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s10194-019-1062-4","volume":"20","author":"T Takeshima","year":"2019","unstructured":"Takeshima T, Wan Q, Zhang Y, Komori M, Stretton S, Rajan N, Treuer T, Ueda K. Prevalence, burden, and clinical management of migraine in China, Japan, and South Korea: a comprehensive review of the literature. J Headache Pain. 2019;20(1):111. https:\/\/doi.org\/10.1186\/s10194-019-1062-4. (PMID: 31805851; PMCID: PMC6896325).","journal-title":"J Headache Pain"},{"issue":"1","key":"2650_CR53","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s10194-021-01236-4","volume":"22","author":"B Lenz","year":"2021","unstructured":"Lenz B, Katsarava Z, Gil-Gouveia R, Karelis G, Kaynarkaya B, Meksa L, Oliveira E, Palavra F, Rosendo I, Sahin M, Silva B, Ulud\u00fcz D, Ural YZ, Varsberga-Apsite I, Zengin ST, Zvaune L, Steiner TJ. Headache service quality evaluation: implementation of quality indicators in primary care in Europe. J Headache Pain. 2021;22(1):33. https:\/\/doi.org\/10.1186\/s10194-021-01236-4. (PMID: 33910500; PMCID: PMC8080333).","journal-title":"J Headache Pain"},{"issue":"10283","key":"2650_CR54","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1016\/S0140-6736(20)32342-4","volume":"397","author":"M Ashina","year":"2021","unstructured":"Ashina M, Buse DC, Ashina H, Pozo-Rosich P, Peres MFP, Lee MJ, Terwindt GM, Halker Singh R, Tassorelli C, Do TP, Mitsikostas DD, Dodick DW. Migraine: integrated approaches to clinical management and emerging treatments. Lancet. 2021;397(10283):1505\u201318. https:\/\/doi.org\/10.1016\/S0140-6736(20)32342-4. (Epub 2021 Mar 25 PMID: 33773612).","journal-title":"Lancet"},{"issue":"1","key":"2650_CR55","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s10194-021-01250-6","volume":"22","author":"BK Kim","year":"2021","unstructured":"Kim BK, Chu MK, Yu SJ, Dell\u2019Agnello G, Han JH, Cho SJ. Burden of migraine and unmet needs from the patients\u2019 perspective: a survey across 11 specialized headache clinics in Korea. J Headache Pain. 2021;22(1):45. https:\/\/doi.org\/10.1186\/s10194-021-01250-6. (Erratum in: J Headache Pain. 2021 Jun 11;22(1):56. PMID: 34030630; PMCID: PMC8146656).","journal-title":"J Headache Pain"},{"key":"2650_CR56","first-page":"1204","volume":"396","author":"GBD","year":"2019","unstructured":"GBD. Diseases and injuries collaborators (2020) global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the global burden of disease study 2019. Lancet. 2019;396:1204\u201322.","journal-title":"Lancet"},{"issue":"1","key":"2650_CR57","first-page":"17","volume":"99","author":"H Ha","year":"2019","unstructured":"Ha H, Gonzalez A. Migraine headache prophylaxis. Am Fam Phys. 2019;99(1):17\u201324.","journal-title":"Am Fam Phys"},{"key":"2650_CR58","doi-asserted-by":"publisher","DOI":"10.1177\/25158163221096867","author":"S Giri","year":"2022","unstructured":"Giri S, Tronvik E, Linde M, et al. The impact of topiramate, botulinum toxin type A, and CGRP-antibodies on medication overuse headache in patients with chronic migraine: a protocol for systematic review and meta-analysis. Cephalalgia Rep. 2022. https:\/\/doi.org\/10.1177\/25158163221096867.","journal-title":"Cephalalgia Rep"},{"issue":"1","key":"2650_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/head.13456","volume":"59","author":"American Headache Society","year":"2019","unstructured":"American Headache Society. The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache. 2019;59(1):1\u201318. https:\/\/doi.org\/10.1111\/head.13456. (Epub 2018 Dec 10. Erratum in: Headache. 2019 Apr;59(4):650-651. PMID: 30536394).","journal-title":"Headache"},{"issue":"2","key":"2650_CR60","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s40120-023-00438-z","volume":"12","author":"E Bentivegna","year":"2023","unstructured":"Bentivegna E, Onan D, Martelletti P. Unmet needs in preventive treatment of migraine. Neurol Ther. 2023;12(2):337\u201342. https:\/\/doi.org\/10.1007\/s40120-023-00438-z. (Epub 2023 Feb 4. PMID: 36738437; PMCID: PMC10043072).","journal-title":"Neurol Ther"},{"key":"2650_CR61","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/j.1526-4610.2009.01595.x","volume":"50","author":"ME Bigal","year":"2010","unstructured":"Bigal ME, Golden W, Buse D, Chen YT, Lipton RB. Triptan use as a function of cardiovascular risk. A population-based study. Headache. 2010;50:256\u201363.","journal-title":"Headache"},{"issue":"11","key":"2650_CR62","doi-asserted-by":"publisher","first-page":"5176","DOI":"10.1007\/s12325-022-02289-w","volume":"39","author":"T Takeshima","year":"2022","unstructured":"Takeshima T, Ueda K, Komori M, Zagar AJ, Kim Y, Jaffe DH, Matsumori Y, Hirata K. Potential unmet needs in acute treatment of migraine in Japan: results of the OVERCOME (Japan) study. Adv Ther. 2022;39(11):5176\u201390. https:\/\/doi.org\/10.1007\/s12325-022-02289-w. (PMID: 36089637; PMCID: PMC9525323).","journal-title":"Adv Ther"},{"key":"2650_CR63","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/S0140-6736(19)31946-4","volume":"394","author":"MD Ferrari","year":"2019","unstructured":"Ferrari MD, Diener HC, Ning X, Galic M, Cohen JM, Yang R, Mueller M, Ahn AH, Schwartz YC, Grozinski-Wolff M, et al. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet. 2019;394:1030\u201340 (Google Scholar, CrossRef).","journal-title":"Lancet"},{"key":"2650_CR64","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1212\/WNL.94.15_supplement.162","volume":"94","author":"W Mulleners","year":"2020","unstructured":"Mulleners W, Kim B-K, Lainez M, Lanteri-Minet M, Aurora S, Nichols R, Wang S, Tockhorn-Heidenreich A, Detke H. A randomized, placebo-controlled study of galcanezumab in patients with treatment-resistant migraine: double-blind results from the CONQUER study (162). Neurology. 2020;94:162.","journal-title":"Neurology"},{"issue":"3","key":"2650_CR65","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S1474-4422(22)00517-8","volume":"22","author":"RB Lipton","year":"2023","unstructured":"Lipton RB, Croop R, Stock DA, Madonia J, Forshaw M, Lovegren M, Mosher L, Coric V, Goadsby PJ. Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial. Lancet Neurol. 2023;22(3):209\u201317. https:\/\/doi.org\/10.1016\/S1474-4422(22)00517-8. (Erratum in: Lancet Neurol. 2023 May;22(5):e7. PMID: 36804093).","journal-title":"Lancet Neurol"},{"issue":"6","key":"2650_CR66","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.3390\/jcm11061656","volume":"11","author":"D Moreno-Ajona","year":"2022","unstructured":"Moreno-Ajona D, Villar-Mart\u00ednez MD, Goadsby PJ. New generation gepants: migraine acute and preventive medications. J Clin Med. 2022;11(6):1656. https:\/\/doi.org\/10.3390\/jcm11061656. (PMID: 35329982; PMCID: PMC8953732).","journal-title":"J Clin Med"},{"issue":"3","key":"2650_CR67","first-page":"935","volume":"290","author":"ML Cohen","year":"1999","unstructured":"Cohen ML, Schenck K. 5-Hydroxytryptamine (1F) receptors do not participate in vasoconstriction: lack of vasoconstriction to LY344864, a selective serotonin (1F) receptor agonist in rabbit saphenous vein. J Pharmacol Exp Ther. 1999;290(3):935\u20139.","journal-title":"J Pharmacol Exp Ther"},{"issue":"9","key":"2650_CR68","doi-asserted-by":"publisher","first-page":"924","DOI":"10.3390\/ph14090924","volume":"14","author":"D Scuteri","year":"2021","unstructured":"Scuteri D, Bagetta G. Progress in the treatment of migraine attacks: from traditional approaches to eptinezumab. Pharmaceuticals (Basel). 2021;14(9):924. https:\/\/doi.org\/10.3390\/ph14090924. (PMID: 34577624; PMCID: PMC8465143).","journal-title":"Pharmaceuticals (Basel)"},{"issue":"6","key":"2650_CR69","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1080\/14740338.2021.1907342","volume":"20","author":"P Martelletti","year":"2021","unstructured":"Martelletti P, Luciani M, Spuntarelli V, Bentivegna E. Deprescribing in migraine. Expert Opin Drug Saf. 2021;20(6):623\u20135. https:\/\/doi.org\/10.1080\/14740338.2021.1907342. (Epub 2021 Mar 25 PMID: 33749470).","journal-title":"Expert Opin Drug Saf"},{"key":"2650_CR70","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2022.2117613","author":"WD Wells-Gatnik","year":"2022","unstructured":"Wells-Gatnik WD, Ambat FDF, Martelletti P. Hesitancies in primary headaches treatments. Expert Rev Neurother. 2022. https:\/\/doi.org\/10.1080\/14737175.2022.2117613. (Epub ahead of print. PMID: 36039939).","journal-title":"Expert Rev Neurother"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02650-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-023-02650-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02650-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T22:07:09Z","timestamp":1705615629000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-023-02650-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,9]]},"references-count":70,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["2650"],"URL":"https:\/\/doi.org\/10.1007\/s12325-023-02650-7","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,9]]},"assertion":[{"value":"15 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Enrico Bentivegna, Silvia Galastri, Dilara Onan and Paolo Martelletti have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}